Optimi Registers 21.9M Shares for Seven Knots Resale — 383% Potential Dilution
OPTH sits 57% above its 52-week low of $3.12 on light trading volume (0.2× avg).
Summary
Optimi Health registered 21.9 million shares for resale by Seven Knots under its $100M equity line — a potential 383% dilution to the current 5.7M share count. The prospectus details VWAP-based pricing at a 3% discount, a $1.5M convertible commitment note, and a 3% placement agent fee.
Key Events · Financing and Capital Events · OPTH
-
21.9M Shares Registered for Resale
Prospectus registers 21,943,260 common shares for Seven Knots, LLC — 21,276,593 purchase shares plus 666,667 commitment shares — representing approximately 383.2% of Optimi's 5,725,867 outstanding shares.
-
VWAP-Based Purchase Mechanics
Seven Knots buys at 97% of the lesser of the day's lowest sale price or VWAP, capped at $2 million per draw and 30% of daily trading volume, with a 4.99% beneficial ownership blocker.
-
Commitment Notes Add Dilution
Seven Knots received a $1.5 million convertible note (plus $500,000 contingent on $7M in draws), convertible at 95% of the 20-day VWAP with a $3.00 floor price — up to 666,667 additional shares.
-
Placement Agent Fee
Joseph Gunnar & Co., LLC receives 3% of gross proceeds from Seven Knots purchases, plus a 3% fee on any other Seven Knots-related fundraising within 12 months of the U.S. IPO.
Analysis · OPTH · Life Sciences
This prospectus registers 21,943,260 common shares for resale by Seven Knots, LLC under the $100 million equity line announced August 14. The registered shares represent approximately 383% of Optimi's 5,725,867 outstanding shares — a massive overhang that could severely depress the stock if Seven Knots sells into the market. The deal is structured as a VWAP-based facility: Optimi can direct purchases at 97% of the lower of the day's low or VWAP, with a $2 million cap per draw and a 4.99% ownership blocker. Seven Knots also received a $1.5 million convertible note (with another $500,000 contingent on $7 million in draws) convertible at 95% of the 20-day VWAP with a $3.00 floor. The company gets no proceeds from the resale itself — only from future draws it elects to make. Against a backdrop of a $5.7 million quarterly net loss and a going-concern warning in the August 14 financials, this facility is a survival lifeline, but the dilution math is brutal for existing holders.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPTH was trading at $4.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28M. The 52-week trading range was $3.12 to $8.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.